Background Since 2006, many countries have implemented publicly funded human
papillomavirus (HPV) immunisation programmes. However, global estimates of the extent …

Background Mortality rates from cervical cancer demonstrate deep inequality in health
between richer and poorer populations. Over 310 000 women died of this preventable …

Background Introduction of human papillomavirus (HPV) vaccination in settings with the
highest burden of HPV is not universal, partly because of the absence of quantitative …

Abstract WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are
analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set …

More than 90% of cervical cancer deaths occur in low-and middle-income countries (LMICs),
which have limited capacity to mount the comprehensive national screening and precancer …

Background Cervical screening and human papillomavirus (HPV) vaccination have been
implemented in most high-income countries; however, coverage is low in low-income and …

Summary Background The Papillomavirus Rapid Interface for Modelling and Economics
(PRIME) has been used around the world to assess the health impact and cost-effectiveness …

While many European Union/European Economic Area (EU/EEA) countries recently
expanded human papillomavirus (HPV) vaccination to boys, HPV vaccine supply is currently …

Background Introduction of human papillomavirus (HPV) vaccination has been slow in low-
income and middle-income countries (LMICs) because of resource constraints and …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …